ArticleJCEM case reports2026
Fournier gangrene in a patient with corticotrophinoma and diabetes treated with sodium-glucose cotransporter 2 inhibitor.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypercortisolism induces immunosuppression, and infections represent the second leading cause of death among patients with Cushing syndrome. We report the case of an adult man with a silent corticotroph pituitary adenoma that evolved into a functioning adrenocorticotropic hormone-secreting tumor. The patient had diabetes mellitus and was treated with dapagliflozin. Prior to transsphenoidal adenomectomy, he developed Fournier gangrene, a necrotizing fasciitis of the perineal and genital regions. Infectious management included debridement, antibiotics, and hyperbaric oxygen therapy. After adequate control of the infection, pituitary surgery was performed, resulting in hypercortisolism remission. Although Cushing syndrome is well known to predispose patients to infections, the association between endogenous hypercortisolism and Fournier gangrene has been scarcely described in the literature. The present case highlights the risk of this severe soft tissue infection in patients with Cushing syndrome. Dapagliflozin and other sodium-glucose cotransporter 2 inhibitors have been investigated as potential contributors to Fournier gangrene in patients with diabetes mellitus, prompting a discussion about the safety of prescribing these agents in the setting of hypercortisolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.